These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 35051605)

  • 1. Xiaoyao Powder in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Liu N; Yang J; Ma W; Li C; An L; Zhang X; Zou Q
    J Ethnopharmacol; 2022 Apr; 288():114999. PubMed ID: 35051605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of Huazhi Rougan granule in the treatment of non-alcoholic fatty liver: a systematic review and meta-analysis.
    Wang T; Song J; Hu J; Feng S; Zhang H; Wang H; Li B
    Ann Palliat Med; 2021 Dec; 10(12):12969-12984. PubMed ID: 33691456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Yang K; Chen J; Zhang T; Yuan X; Ge A; Wang S; Xu H; Zeng L; Ge J
    Front Immunol; 2022; 13():949746. PubMed ID: 36159792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review.
    Nie Q; Li M; Huang C; Yuan Y; Liang Q; Ma X; Qiu T; Li J
    J Transl Med; 2024 Mar; 22(1):225. PubMed ID: 38429794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xuefu Zhuyu decoction for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis.
    Liu J; Dong B; Yang L; Huang W; Tang S
    Medicine (Baltimore); 2021 May; 100(19):e25358. PubMed ID: 34106587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.
    Fatima K; Moeed A; Waqar E; Atif AR; Kamran A; Rizvi H; Suri NF; Haider H; Shuja SH; Khalid M; Minhas AMK
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101816. PubMed ID: 34607067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of traditional Chinese medicine combined with Silibinin on nonalcoholic fatty liver disease: A meta-analysis and systematic review.
    Zhang X; Jiang Z; Jin X; Zhou Q
    Medicine (Baltimore); 2024 Feb; 103(5):e37052. PubMed ID: 38306552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
    PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials.
    Jalali M; Rahimlou M; Mahmoodi M; Moosavian SP; Symonds ME; Jalali R; Zare M; Imanieh MH; Stasi C
    Pharmacol Res; 2020 Sep; 159():104799. PubMed ID: 32278041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional foods and dietary supplements in the management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Wang LL; Zhang PH; Yan HH
    Front Nutr; 2023; 10():1014010. PubMed ID: 36866059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Jalali M; Mahmoodi M; Mosallanezhad Z; Jalali R; Imanieh MH; Moosavian SP
    Complement Ther Med; 2020 Jan; 48():102283. PubMed ID: 31987259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of HuoXueHuaYu therapy for nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trial.
    Cai Y; Liang Q; Chen W; Chen M; Chen R; Zhang Y; Xiao Y; Chen L
    BMC Complement Altern Med; 2019 Jul; 19(1):178. PubMed ID: 31324247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of bicyclol on blood biomarkers of NAFLD: a systematic review and meta-analysis.
    Li H; Liu NN; Peng ZG
    BMJ Open; 2020 Dec; 10(12):e039700. PubMed ID: 33277283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herbal medicines for fatty liver diseases.
    Liu ZL; Xie LZ; Zhu J; Li GQ; Grant SJ; Liu JP
    Cochrane Database Syst Rev; 2013 Aug; (8):CD009059. PubMed ID: 23975682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Sun L; Deng C; Gu Y; He Y; Yang L; Shi J
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101876. PubMed ID: 35321843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.
    Yang JM; Sun Y; Wang M; Zhang XL; Zhang SJ; Gao YS; Chen L; Wu MY; Zhou L; Zhou YM; Wang Y; Zheng FJ; Li YH
    World J Gastroenterol; 2019 Sep; 25(34):5105-5119. PubMed ID: 31558860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of different natural products in patients with non-alcoholic fatty liver disease-A network meta-analysis of randomized controlled trials.
    Liu H; Li Y; Jin Y; Li X; Wang D; Yu X; Jiang Z; Yin G; Chen S; Zhang X; Meng D; Yu W; Jiang W; Zhang F
    Phytother Res; 2024 Jul; 38(7):3801-3824. PubMed ID: 38886838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
    Fan S; Shi X; Yao J; Zhong M; Feng P
    Rev Esp Enferm Dig; 2020 Aug; 112(8):627-635. PubMed ID: 32496108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.